Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 179

Similar articles for PubMed (Select 24390322)

1.

Feline immunodeficiency virus envelope glycoproteins antagonize tetherin through a distinctive mechanism that requires virion incorporation.

Morrison JH, Guevara RB, Marcano AC, Saenz DT, Fadel HJ, Rogstad DK, Poeschla EM.

J Virol. 2014 Mar;88(6):3255-72. doi: 10.1128/JVI.03814-13. Epub 2014 Jan 3.

2.

Feline tetherin is characterized by a short N-terminal region and is counteracted by the feline immunodeficiency virus envelope glycoprotein.

Celestino M, Calistri A, Del Vecchio C, Salata C, Chiuppesi F, Pistello M, Borsetti A, Palù G, Parolin C.

J Virol. 2012 Jun;86(12):6688-700. doi: 10.1128/JVI.07037-11. Epub 2012 Apr 18.

3.

Feline tetherin efficiently restricts release of feline immunodeficiency virus but not spreading of infection.

Dietrich I, McMonagle EL, Petit SJ, Vijayakrishnan S, Logan N, Chan CN, Towers GJ, Hosie MJ, Willett BJ.

J Virol. 2011 Jun;85(12):5840-52. doi: 10.1128/JVI.00071-11. Epub 2011 Apr 13.

4.

Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration.

Gupta RK, Mlcochova P, Pelchen-Matthews A, Petit SJ, Mattiuzzo G, Pillay D, Takeuchi Y, Marsh M, Towers GJ.

Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20889-94. doi: 10.1073/pnas.0907075106. Epub 2009 Oct 28.

5.

Vpu downmodulates two distinct targets, tetherin and gibbon ape leukemia virus envelope, through shared features in the Vpu cytoplasmic tail.

Lucas TM, Janaka SK, Stephens EB, Johnson MC.

PLoS One. 2012;7(12):e51741. doi: 10.1371/journal.pone.0051741. Epub 2012 Dec 19.

6.

Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal.

Lopez LA, Yang SJ, Hauser H, Exline CM, Haworth KG, Oldenburg J, Cannon PM.

J Virol. 2010 Jul;84(14):7243-55. doi: 10.1128/JVI.02636-09. Epub 2010 May 5.

7.

Palmitoylation of the feline immunodeficiency virus envelope glycoprotein and its effect on fusion activity and envelope incorporation into virions.

González SA, Paladino MG, Affranchino JL.

Virology. 2012 Jun 20;428(1):1-10. doi: 10.1016/j.virol.2012.03.005. Epub 2012 Apr 12.

8.

Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein.

Le Tortorec A, Neil SJ.

J Virol. 2009 Nov;83(22):11966-78. doi: 10.1128/JVI.01515-09. Epub 2009 Sep 9.

9.

Ancient adaptive evolution of tetherin shaped the functions of Vpu and Nef in human immunodeficiency virus and primate lentiviruses.

Lim ES, Malik HS, Emerman M.

J Virol. 2010 Jul;84(14):7124-34. doi: 10.1128/JVI.00468-10. Epub 2010 May 5.

10.

Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2.

Jia B, Serra-Moreno R, Neidermyer W, Rahmberg A, Mackey J, Fofana IB, Johnson WE, Westmoreland S, Evans DT.

PLoS Pathog. 2009 May;5(5):e1000429. doi: 10.1371/journal.ppat.1000429. Epub 2009 May 15.

11.

Equine tetherin blocks retrovirus release and its activity is antagonized by equine infectious anemia virus envelope protein.

Yin X, Hu Z, Gu Q, Wu X, Zheng YH, Wei P, Wang X.

J Virol. 2014 Jan;88(2):1259-70. doi: 10.1128/JVI.03148-13. Epub 2013 Nov 13.

12.
13.

Counteraction of tetherin antiviral activity by two closely related SIVs differing by the presence of a Vpu gene.

Nikovics K, Dazza MC, Ekwalanga M, Mammano F, Clavel F, Saragosti S.

PLoS One. 2012;7(4):e35411. doi: 10.1371/journal.pone.0035411. Epub 2012 Apr 17.

14.

Feline immunodeficiency virus (FIV) neutralization: a review.

Hosie MJ, Pajek D, Samman A, Willett BJ.

Viruses. 2011 Oct;3(10):1870-90. doi: 10.3390/v3101870. Epub 2011 Oct 13. Review.

15.

Feline immunodeficiency virus env gene evolution in experimentally infected cats.

Kraase M, Sloan R, Klein D, Logan N, McMonagle L, Biek R, Willett BJ, Hosie MJ.

Vet Immunol Immunopathol. 2010 Mar 15;134(1-2):96-106. doi: 10.1016/j.vetimm.2009.10.015. Epub 2009 Nov 7.

PMID:
19897254
16.

Anti-tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts.

Lopez LA, Yang SJ, Exline CM, Rengarajan S, Haworth KG, Cannon PM.

J Virol. 2012 May;86(10):5467-80. doi: 10.1128/JVI.06280-11. Epub 2012 Mar 7.

17.

Anti-tetherin activities in Vpu-expressing primate lentiviruses.

Yang SJ, Lopez LA, Hauser H, Exline CM, Haworth KG, Cannon PM.

Retrovirology. 2010 Feb 18;7:13. doi: 10.1186/1742-4690-7-13.

18.
19.

The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin.

Pardieu C, Vigan R, Wilson SJ, Calvi A, Zang T, Bieniasz P, Kellam P, Towers GJ, Neil SJ.

PLoS Pathog. 2010 Apr 15;6(4):e1000843. doi: 10.1371/journal.ppat.1000843.

20.

HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef.

Sauter D, Hué S, Petit SJ, Plantier JC, Towers GJ, Kirchhoff F, Gupta RK.

Retrovirology. 2011 Dec 15;8:103. doi: 10.1186/1742-4690-8-103.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk